Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-248 Monotherapy or with Anti-CD20 Antibodies in Mature B-cell Malignancies
NCT06351527Phase 1Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Apr 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of mesutoclax in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL) (4 arms), sponsored by InnoCare Pharma. Primary endpoints: Dose-Limiting Toxicity at 49 days and Safety and Tolerability of ICP-248 at 5 years. Started Apr 2024; status: recruiting.
02
Drugs
mesutoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06351527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06351527.